Table 1. RAPCHEM outcomes per risk and treatment subgroups.

Risk group	RAPCHEM approach	Treatment subgroup†
		Per protocol			Protocol deviations—less than per protocol			Protocol deviations—more than per protocol
		Recurrence rate (%)	Number of patients		Recurrence rate (%)	Number of patients		Recurrence rate (%)	Number of patients
Low risk (N=291)	ALND ± RNI‡	2.3	162		NR	2		1.9	73
	SLNB ± RNI		19			0			36
Intermediate risk (N=370)	ALND ± RNI‡	1.0	174		3.2	54		3.8	94
	SLNB ± RNI		30			10			12
High risk (N=177)	ALND + RNI‡	1.4	125		8.4	7		N/A	–
	SLNB + RNI		32			18			–

^†, number of patients in each subgroup is taken from Boersma et al. (20); ^‡, with omission of the operated part of the axilla. RAPCHEM, radiotherapy after primary chemotherapy study (19); ALND, axillary lymph node dissection; N/A, not applicable; RNI, regional nodal irradiation; SLNB, sentinel lymph node biopsy; NR, not reported.